A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Subjects With Varying Degrees of Renal Function
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Cimlanod (Primary)
- Indications Acute heart failure
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 12 Apr 2018 Planned End Date changed from 30 Sep 2018 to 16 Sep 2018.
- 12 Apr 2018 Planned primary completion date changed from 30 Sep 2018 to 16 Sep 2018.
- 12 Apr 2018 Status changed from not yet recruiting to recruiting.